Uremic Toxins and Hemodiafiltration

Since the seminal work on classification, concentration, and interindividual variability of uremic toxins, new aspects of ‘modern’ dialysis treatment have emerged. Uremic toxins (UT) have been identified and related to higher rates of morbidity and mortality in dialysis patients. Find out more about their effects on cardiovascular disease and how to improve the removal of UT during dialysis. Usual doses of erythropoiesis-stimulating agents (ESAs) have limited impact on chronic kidney disease-associated anemia. This session will discuss online high-volume hemodiafiltration and the remediation of ESA resistance in patients suffering from uremic inflammation, in reference to the REDERT study.

Press the CLICK HERE or Register button to view.